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Abstract
Clinical Practice Guideline for Thromboembolism
Angela Miller MSN, FNP-BC, ONP-C

Background: The morbidity associated with venous thromboembolism often goes
unrecognized. Identifying patient populations at risk for venous thromboembolism and
implementing evidence-based guidelines can decrease the number of untoward effects of this
disease. Clinical pathway guidelines are valuable tools needed by nurses in the prevention and
treatment of disorders for patients. Education of the guideline can increase knowledge and
understanding of what prevention, interventions, and treatment are available for the orthopaedic
patient and how to apply this knowledge to everyday patient care.

Objective: To educate orthopaedic nurses on the clinical practice guidelines of
thromboembolism.

Method: Incorporate the education of thromboembolism in an orthopaedic class intended for
registered nurses studying for the national orthopaedic exam.

Population: Twenty-three registered nurses from the Mid-Ohio Valley employed at Selby
General Hospital.

Expected Outcome: To calculate a statistically difference in the scores of a pre test and a post
test given to the nurses enrolled in the class on the prevention and treatment of
thromboembolism.
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Introduction
Thromboembolic disease or venous thromboembolism (VTE) is an important public health
problem. A total of two million Americans suffer from VTE each year; approximately 200,000
deaths annually result from pulmonary embolism (PE) (Fekrazad et al. 2009). The morbidity
associated with VTE often goes unrecognized. The morbidity includes serious long term
complications such as chronic edema, chronic venous insufficiency, chronic pain, and recurrent
venous ulceration which are known as post-thrombotic syndrome (Kahn 2006). VTE is
preventable in many instances. Identifying patient populations at risk for VTE and implementing
evidence-based guidelines can decrease the number of untoward effects of this disease (Passman,
2010).

Purpose
The purpose of the VTE guideline is to provide evidence-based information that assists in the
identification of populations at risk for the disease as well as provide evidence- based
interventions aimed at prophylaxis and prevention. Empowering nurses with the guideline would
allow the nurse to take responsibility for assessing patients for VTE and provide appropriate
prophylaxis. This allows nurses to help reduce the number of VTE incidences and the associated
consequences. Nurses are in a crucial position to help improve orthopaedic outcomes in relation
to thromboembolism of the patient by providing evidence-based care.
Definition of Problem
Approximately 700,000 primary total hip and knee replacements are performed each year in
the United States. The number is expected to grow to over 3.5 million in 2030 (AAOS, 2011).
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On average, about 2 to 3% of people undergoing total joint replacement would end up with a
symptomatic DVT or PE (AAOS, 2011). The orthopaedic nurse needs competency in performing
two critical procedures in detecting thromboembolism. First, educate patients on prevention of
thromboembolism. Second, identify signs and symptoms of thromboembolism for timely
intervention.
Goals of Clinical Practice Guideline
The goal for the guideline is the significance of addressing orthopaedic trauma and total joint
patients in developing VTE. Orthopaedic trauma and total joint patients are among the highest
risk groups for developing VTE. The guidelines would provide evidence- based interventions
aimed at decreasing VTE events. VTE is considered to be one of the most preventable causes of
death in the hospital (Mitchota, 2007). Typically hospitals adhere to the ACCP guidelines.
However, the AAOS guidelines are more appropriate for orthopaedic patients. Therefore, it is
important to educate orthopaedic nurses on the differences of these guidelines and the care
needed for the orthopaedic patient.
During the last decade, the American College of Chest Physicians (ACCP) and the American
Academy of Orthopaedic Surgeons (AAOS) developed their own guidelines for prevention of
venous thromboembolism which were not in agreement which posed dilemmas for those
managing the care of these patients. The guidelines were also not congruent with the guidelines
set forth by the Surgical Care Improvement Project (SCIP). The SCIP is a national partnership
that was developed in 2003 by the Centers for Medicare and Medicaid Services (CMS), and the
Centers for Disease Control (CDC). Other SCIP steering committee organizations include the
American College of Surgeons, the American Hospital Association, The Joint Commission, the
American Society of Anesthesiologists, the Association of PeriOperative Registered Nurses
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(AORN), the Agency for Healthcare Research and Quality, and the Department of Veterans
Affairs. These organizations are committed to improving the safety of surgical care through the
reduction of postoperative complications by utilizing evidence-based core measures (Drake,
2011).
Search Strategy

The following databases were searched: National Guidelines Clearinghouse, The Cochrane
Library, PubMed, CINAHL, Medline, and Academic Search. The search was limited to only
articles written in English. No limits were placed when the articles were published. Only original
studies were used form peer reviewed journals. The following key words were included in the
search: pulmonary embolism; venous thromboembolism; deep vein thrombosis; and clinical
guidelines.

Assessment of Scientific Evidence
Prior to 2012, the ACCP and the AAOS independently published guidelines for prevention of
VTE in the orthopaedic patient. These guidelines proposed very different approaches to
managing these patients which caused confusion and wide variations in practice. The ACCP 8th
Consensus guidelines were the most widely used in most clinical practices but often resulted in
excessive bleeding (Bozic, Vail, Pekow et al., 2010). The differences in guidelines were as a
result of each different organization using different endpoints for evaluating the efficacy of VTE
prophylactic drugs. The ACCP used venographically proven DVT as its endpoint while the
AAOS used excessive bleeding as its endpoint. The problem with bleeding as an endpoint is that
the ACCP defined major bleeding as life threatening intracranial, intraabdominal or intraocular
bleeding and requiring at least two units of packed red cells or decrease of hemoglobin more than
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2 g/dL compared with relevant postoperative level (Bozic, Vail, Pekow et al., 2010). Those
criteria rarely apply to arthroplasty patients. Galat et al (2009) reported that patients with wound
complications of bleeding requiring reoperation within 30 days of TKA were 10 times more
likely to have subsequent major surgery and associated morbidities than those without. However,
failure to meet the ACCPs strict criteria of major bleeding event resulted in under reporting of
bleeding complications in many studies. There were also concerns about conflicts of interest that
appeared in the ACCP guidelines.
Due to the many concerns raised regarding the ACCP guidelines, the AAOS formed its
DVT/PE workgroup in 2007 and issued its own revised recommendations in 2011 by reviewing
the available literature on VTE with symptomatic DVT, PE, and mortality as endpoints (Mont et
al., 2011).The goal was to achieve more balance between minimizing risk and maximizing
efficacy, while minimizing conflicts of interest during the guideline development. Patients were
classified based on their medical history to identify their risk of VTE and bleeding. The AAOS
guidelines were in conflict with the ACCP guidelines until the ninth edition of the ACCP
recommendations, which was published in 2012 (Falck-Yetter et al. as cited in Bozic, Vail,
Pekow et al., 2010). Both of those guidelines, for the first time, included aspirin as an accepted
therapeutic modality for the prevention of VTE.
The alignment of the major recommendations between the AAOS and the ACCP also are now
aligned with the SCIP VTE guidelines.
The SCIP VTE guidelines set forth include:

* SCIP-VTE-1. This measure states that surgery patients will have recommended VTE
prophylaxis ordered. VTE prophylaxis starts with identification of risk factors, including the
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patient having surgery (higher risk with hip or knee surgery), trauma to lower extremities,
increasing age (older than age 40), hormonal therapy, chemotherapy, central line catheter
placement, immobility, obesity, varicose veins, and pregnancy (antepartum and postpartum).
There are a number of risk assessments scoring tools available to assist in the determination of
patient risk severity. Determining if the patient is at low, moderate, or high risk for VTE will
guide the team to select the prophylactic treatment. As soon as a patient is admitted to the
inpatient unit or is known to be staying more than 24 hours, a risk assessment needs to be
completed. After the risk level is assigned, the appropriate intervention can be ordered and
implemented.

Interventions are separated into two categories: nonpharmacologic and pharmacologic. The
first intervention is frequent and early ambulation. The second nonpharmacologic intervention is
the use of graduated compression stockings or intermittent pneumatic compression devices.
Nurses need to know the importance of applying and using these devices for patients with
limited mobility. Patients identified as moderate or high risk will also receive pharmacologic
intervention of a low-dose unfractionated or low-molecular-weight heparin.

* SCIP-VTE-2. This measure states that surgical patients will receive appropriate VTE
prophylaxis within 24 hours before surgery to 24 hours after surgery. Again, the timing of postop medication administration is important. Organizations using best practice alerts may improve
their outcomes by getting prophylaxis ordered and implemented early (Drake, 2011).

Although guidelines issued by the AAOS and the ACCP are valuable resources on the use of
VTE prophylaxis, only the SCIP VTE prophylaxis measures are tied to CMS pay-forperformance programs. Thus, hospitals must ensure that they conform to the SCIP measures for
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VTE prophylaxis to qualify for bonus payments (McKee, 2013). This is critical information for
the nurse caring for the high risk orthopaedic patient to know.
Gaps in the Literature
There is considerable evidence in the literature that provides a vast array of treatment for
thromboembolism, however there continues to remain a gap in the implementation of these
treatments (Passman, 2010).

The guidelines have been vastly underused even with all of the

supporting evidence. One reason for the lack of implementation may be the lack of consensus
among providers for the best treatment options. The Surgical Care Improvement project (SCIP)
was established as a collaborative effort between the Centers for Medicare and Medicaid
Services (CMS) and the Joint Commission (Passman, 2010). In 2010 the SCIP project included
the Agency for Healthcare Research and Quality, American College of Surgeons, American
Hospital Association, American Society of Anesthesiologists, Centers for Disease Control and
Prevention, CMS, Department of Veterans Affairs, Institute for Healthcare Improvement, and the
Joint Commission. The focus of the SCIP project was to prevent surgery complications that have
a relative high incidence and cost. The SCIP program targeted VTE. Haralson describes the
four measures that relate to the SCIP guideline for VTE.
Thromboembolism has become a mandated quality of care, however the economic
manifestations of this care have yet to be realized (Passman, 2010). There continues to remain
data that accurately assess the total economic burden for VTE. The estimated total cost on the
United Stated for VTE is $3.2 to $15.5 billion per year (Cundiff, 2004). In the United States
there are as many as 900,000 that develop a DVT or a PE per year and as many as 300,000
deaths are attributed to VTE per year (Heit, Cohen, & Anderson, 2005). The AHRQ Healthcare
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and Utilization Project estimated the cost for an inpatient to be $10,000 per DVT and $20,000
per PE (Maynard & Stein, 2008). Another study found direct patient cost for DVT to be $17,512
and $18,310 for a PE (MacDougall et al. 2006). Also, an estimated $18,310 can be added to
hospital costs for added complications from a VTE (Dimick et al. 2004). The patient that
sustains a VTE not only has the acute hospital costs, but also chronic complication costs. It is
estimated that a patient that sustains a VTE has an incidence of 7-13% to have a recurrence
within a year and a 30% recurrence within 5 years (Cushman et al. 2004).
Further research is needed to determine the most efficient translation of recommendations
from research to the actual treatment of the patient. Both the ACCP and AAOS agree that the
most important goal is to prevent a pulmonary embolism. The ACCP looks at both pulmonary
embolism and deep vein thrombosis as a measurable outcome and the AAOS looks at only a
pulmonary embolism as a measurable outcome. Therefore, the AAOS concentrates primarily on
pulmonary embolism only and does not test routinely for deep vein thrombosis. The ACCP
includes both asymptomatic and symptomatic deep vein thrombosis detected by venography as a
measure of the efficiency of thrombophylaxis in the prevention of VTE. The AAOS rejects this
and states that the link between DVT and VTE has not been proven (Eikelboom et al. 2009).
The ACCP believes that the AAOS recommendations were based on experts rather than
scientific research. The AAOS states that the ACCP fails to look at the increased bleeding risk
associated with their recommendations (Knesk, Peterson, & Marke, 2012). The increased
bleeding risk associated with the post surgical patient may put the patient at increased infection
risk.
Pathophysiology
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Venous thrombosis is the formation of blood clots in low blood flow veins that are composed
mainly of red blood cells trapped in a fibrin network. In orthopaedic patients, clots frequently
are seen in deep veins in the calf or thigh vessels. Clots tend to form at valve cusps in these
veins. These clots are known as venous thrombosis. A pulmonary embolism (PE) is a clot that
has broken free from the inner layer of the vein. The clot travels through the venous system and
eventually migrates to the pulmonary venous circulation and blocks blood flow resulting in
serious interruption in oxygen exchange at the alveolar-capillary membrane. If the clot is large
enough to totally occlude the pulmonary vein, abrupt and often fatal right sided heart failure
(called cor pulmonale) can occur (Patel & Brenner, 2014; Schwartz & Rote, 2014).
Virchow (Welsh, 2010) identified the triad of factors which contribute to clot formation. The
triad describes how venous stasis-alterations in blood flow can lead to sluggish circulation. This
happens after surgery when immobile patients have a reduction in the contractions of muscles in
the lower leg. The reduction in the contractions of the muscles leads to stagnant blood that can
trigger endothelial wall damage and lead to thrombus formation (Welsh, 2010). Vessel wall
damage occurs by the kinking of major vessels (hip dislocation), trauma, indwelling catheters, or
scarring by previous clots. Endothelial damage to the vein wall can occur which can activate the
clotting cascade leading to increased thrombosis (Coleridge-Smith, 1990).
Blood coagulabilty in the process of clot formation can be due to inherited disorders (Factor
V Leiden, protein C or S deficiency), cancer, estrogen therapies and major surgery. Patients that
have congenital thrombophilia generally remain asymptomatic until their clotting disorder faces
a challenge such as surgery (Mammen, 1992). It is often a combination of factors which leads to
clot formation.
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Orthopaedic patients are at risk for all three factors of Virchow triad in the perioperative
period: changes in blood coagulation, changes in the vessel wall, and changes in blood flow. In
addition the following risk factors put the orthopaedic patient at risk: surgery; trauma, especially
to the lower extremities; immobility; malignancy; history of DVT; older age; pregnancy or
postpartum period; taking estrogen-containing oral contraceptives; inflammatory bowel disease;
obesity; smoking; and varicose veins (Geerts et al. 2008).
Patient Care Management
A multi-modal approach to VTE prevention is the accepted standard of care with orthopaedic
joint replacement and hip fracture patients. The ACCP (2012) recommends a combination of
pharmacologic and mechanical thromboprophylaxis for patients undergoing major orthopaedic
surgery such as total hip arthroplasty (THA), total knee arthroplasty (TKA), and hip fracture
surgery (HFS). The use of dual therapy with pharmacologic and mechanical prophylaxis was
found to be superior to no prophylaxis. For patients undergoing a THA or a TKA the use of an
intermittent pneumatic compression device (IPCD) is recommended with one of the following
pharmacologic measures for a minimum of 10 to 14 days- low-molecular-weight heparin
(LMWH), fondaparinux, apixaban, dabigatran, rivaroxaban, low-dose unfractionated heparin
(LDUH), warfarin therapy, or aspirin. For patients undergoing HFS, the recommendation is to
use an IPCD with one of the following for a minimum of 10 to 14 days; LMWH, fondaparinux,
LDUH, adjusted-dose VKA, or aspirin. Though the minimum recommendation for the length of
treatment is 10-14 days it is also the recommendation of ACCP to extend the
thromboprophylaxis in the outpatient period for up to 35 days from the day of surgery.
Additionally, though ACCP supports the use of the above listed pharmacologic prophylaxis
options for THA, TKA, and HFS patients the recommended preference for pharmacologic
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prophylaxis is LMWH. For patients receiving LMWH as thromboprophylaxis the
recommendation is to start the medication either 12 hours or more preoperatively or 12 hours or
more postoperatively rather than within 4 hours or less preoperatively or 4 hours or less
postoperatively.
Thromboprophylaxis increases the risk for bleeding. If patients are at an increased risk for
bleeding the recommendation is to use an IPCD or no prophylaxis. When patients decline
treatments or are unable or unwilling to do injections or use IPCDs it is recommended to use
apixaban or dabigatran (alternatively rivaroxaban or adjusted-dose VKA if apixaban or
dabigatran are unavailable). When there are contraindications to both pharmacologic and
mechanical thromboprophylaxis the patient is at risk for increased risk of bleeding, the
recommendation is against the use an inferior vena cava (IVC) filter placement for primary
prevention.
The AAOS (2011) recommend against routine post-operative duplex ultrasonography
screening of patients who have undergone elective THA or TKA. Patients undergoing elective
THA or TKA are already at an increased risk of VTE As these patients are already at an
increased the recommendation is to identify and assess those patients at a higher risk for VTE
development. The practitioner should evaluate the patient and determine whether these patients
have a history of venous thromboembolism. Patients undergoing elective THA or TKA
which/who are at risk for bleeding and bleeding-associated complications should be assessed for
known bleeding disorders like hemophilia and presence of active liver disease which further
increase the risk for bleeding and bleeding-associated complications.
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Another recommendation is that patients should discontinue antiplatelet agents (e.g., aspirin,
clopidogrel) before undergoing elective THA or TKA. The use of pharmacologic agents and/or
mechanical compressive devices for the prevention of VTE disease in patients undergoing
elective THA or TKA is dependent on the patient’s risk. For patients not at elevated risk of
VTE, beyond that of the surgery, the recommendation is to use pharmacologic agents and/or
mechanical compressive devices. For patients who have had a previous VTE, the
recommendation is to use pharmacologic prophylaxis and mechanical compressive devices.
Though there is not strong evidence, patients undergoing elective THA or TKA and who have a
known bleeding disorder (e.g., hemophilia) and/or active liver disease, the recommendation are
to use mechanical compressive devices for preventing VTE. Additionally, early mobilization
following THA or TKA is recommended. Early mobilization is of low cost, minimal risk to the
patient, and consistent with current practice. Neuraxial anesthesia (such as intrathecal, epidural,
and spinal) was recommended for patients undergoing elective THA or TKA. Neuraxial blocks
have been shown to have no effect on the evidence of VTE and may also help to limit blood loss
during surgery. The use of an inferior Vena Cava (IVC) filter was not recommended for or
against.
Assessment
All patients should be assessed pre-operatively for elevated risk of VTE. A written
thromboprophylaxis policy should be in place for the institution along with preprinted orders,
periodic audit, and feedback.
The physical exam for DVT includes


pain and tenderness at or below the site of the thrombosis;
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swelling of the affected leg;



elevating the leg may lessen the swelling, however, the swelling returns with ambulation;



pitting edema confined to the symptomatic leg;



redness of the affected extremity; and



homan’s sign (forced dorsiflexion of the foot causing discomfort in the calf) is present in
less than one third of the patients and not specific or sensitive for DVT

The physical exam should be documented in the pre assessment nursing notes prior to surgery.
Current mainstay for determining DVT probability is the Wells Score.
Risk score interpretation (probability of DVT): 3 points: high risk (75%); 1 to
2 points: moderate risk (17%); < 1 point: low risk (3%).
Active cancer?

+1

Bedridden recently >3 days or major surgery within four weeks?

+1

Calf swelling >3cm compared to the other leg?

+1

Collateral (nonvaricose) superficial veins present?

+1

Entire leg swollen?

+1

Localized tenderness along the deep venous system?

+1

Pitting edema, greater in the symptomatic leg?

+1

Paralysis, paresis, or recent plaster immobilization of the lower extremity +1
Previously documented DVT?

+1

Alternative diagnosis to DVT as likely or more likely?

-2

(Adapted from Duggar, 2014)

The physical exam for PE includes
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severe dyspnea;



chest pain;



hypoxia;



apprehension;



confusion;



anxiety;



Tachypenia;



Tachycardia;



diminished breath sounds;



fever;



diaphoresis;



hemoptysis;



pleuritic chest pain; and



a Split S2 may be heard which is a systolic murmur over the pulmonary artery due to an
obstruction.

The physical exam for the PE should be documented in the pre assessment nursing notes prior to
surgery.
The medical management of DVT includes physical measures, mechanical prophylaxis, and
pharmacological agents with contraindications. Physical measures of DVT include:


Patients are to be out of bed, sitting in a chair several times a day, and ambulating as
tolerated.



Elevate the foot of the bed. and
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Patients to be instructed to actively dorsiflex and plantar flex the ankle and toes. This
exercise should be performed in sets of 10 to 20 every half hour when the patient is
awake.

Mechanical prophylaxis for DVT assists with the venous return in patients and can be
intermittent external pneumatic compression (IPC) or anti-embolism stockings (AES).
Intermittent external pneumatic compression (IPC) provides external compression of the lower
extremities, promoting venous return. Contraindications of IPC includes


a known or suspected DVT;



local leg conditions;



arteriosclerosis vascular disease or neuropathy;



massive edema of legs or pulmonary edema;



extreme deformity of the legs; and



patient refusal to wear correctly (Welch, 2010).

Anti-embolism stockings (AES) provide continuous stimulation of linear blood flow, prevent
venous dilation (Coleridge-Smith et al., 1991), and stimulate endothelial fibrinolytic activity
(Arcelus et al., 1995). Contraindications of AES includes


local leg conditions;



arteriosclerosis vascular disease or neuropathy;



massive edema of legs or pulmonary edema;



extreme deformity of the legs;



allergy to material; and



patient refusal to wear correctly (Welch, 2010).
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Multiple pharmacologic agents can be used with thromboembolism. It is important to start
treatment with parenteral anticoagulation for DVT or PE while awaiting diagnostic test results
unless low clinical suspicion of VTE (LMWH or fondaparinux recommended over heparin).
Continue treatment at home if circumstances allow. If contraindications for pharmacologic
therapy, the use of mobile IPC is recommended as long as there is a chip that can be interrogated
to check for compliance.
Therapy length is based on underlying risk factor. Post-operative patient is 3 months.
Provoked non-surgical with transient risk is 3 months (assuming that risk factor is resolved).
Unprovoked proximal is 3 months, then reevaluate for risk-benefit (may stop if high bleeding
risk, otherwise extended therapy is recommended). Unprovoked isolated distal DVT is 3
months. Second unprovoked VTE needs extended therapy. Therapy is only 3 months for
patients at a high bleeding risk. Active cancer needs extended therapy. Reassess extended
therapy patients for continued treatment at periodic intervals.
Unfractionated heparin works by Heparin-activation of antithrombin III that inactivates
thrombin and factor Xa in the coagulation process. Unfractionated heparin requires monitoring
with the goal of maintaining an elevated activated partial thromboplastin time (APTT) (Knesek et
al., 2012). Heparin is given in a bolus of 80units/kg or fixed 5000 units. Continuous infusion at
18units/kg/hr or fixed 1000 units/hr is maintained. Outpatient therapy is 333 units/kg as the first
dose, then 250 units/kg (no aPPT monitoring recommended).
Warfarin-affects prothrombin time by competing with vitamin K. Warfarin is given as 10mg
daily for 2 days, then dose per INR for sufficiently healthy patients, otherwise start with 5 mg
daily. Start warfarin on day 1 or 2. Once the patient is stabilized on a specific dose, INR
measurements are done at 1 to 2 week intervals (Knesek et al., 2012).
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Low molecular weight heparin (LMWH) is administered via the subcutaneous route with
daily or twice daily dosing without coagulation monitoring. LMWH reduces
hypercoagulability by inhibiting coagulation proteins through increased antithrombin action
(Knesek et al., 2012). Use LMWH over dabigatran or rivaroxaban if unable to take warfarin
(lack of data when 2012 CHEST guidelines published). Use LMWH over warfarin in cancer
patients for long term treatment.
Factor Xa inhibitors-Rivaraxaban (Xarelto) should be taken orally once daily in 10-mg doses.
The initial dose should be taken 6 to 10 hours after surgery, provided that hemostasis has been
established. Recommended treatment durations are 4 weeks for patients having major hip
surgery and 2 weeks for patients having major knee surgery (Eymin & Jaffer, 2013).
Discontinue injectable anticoagulation when starting rivaroxaban. Factor Xa inhibitor
Fondaparinux (Arixtra) is a synthetic polysaccharide derived from the antithrombin-binding
region of heparin. Fondaparinux is administered via the subcutaneous route once daily
(Yamaguchi et al., 2010).
Aspirin inhibits the production of thromboxane creating an antiplatelet effect (Autar, 2006).
The AAOS recommends the use of ASA for patients with no history of malignancy, no previous
clots, and no history of thrombophilia for the prevention of VTE (Knesek et al., 2012). Optimal
dose is 160 mg by mouth every day.
Contraindications of pharmacological prophylaxis includes


active bleeding;



bleeding disorders such as liver failure and hemophilia;



concurrent use of anticoagulants;
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lumbar puncture, epidural or spinal anesthesia within the previous 4 hours, or expected
within the next 12 hours;



acute stroke;



platelets less than 75 x 109/l; and



hypertension (230/120 mmHg or more) (Welch, 2010).

Treatment of DVT includes anticoagulation for 3 months, noninvasive tests for 10 to 14 days,
or surgery.
Management of PE can be done with medication or surgery. The anticoagulation medication
can be Heparin, LMWH, or Warfarin. Thrombolytic therapy is used with massive PE in
combination with heparin. Agents used include: streptokinase, urokinase, and recombinant
tissue-type plasminogen. Surgical and invasive procedures can be an IVC filter, prophylactic
IVC filter, pulmonary embolectomy, and or supplemental oxygen. Contraindications of
pharmacological prophylaxis includes


active bleeding;



bleeding disorders such as liver failure and hemophilia;



concurrent use of anticoagulants;



lumbar puncture, epidural or spinal anesthesia within the previous 4 hours, or expected
within the next 12 hours;



acute stroke;



platelets less than 75 x 109/l; and



severe hypertension (230/120 mmHg or more) (Welch, 2010).

There are certain pregnancy and lactations considerations
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LMWH preferred over unfractionated heparin;



Warfarin is contraindicated (able to be used in breastfeeding);



Patients on warfarin should be changed to therapeutic LMWH when positive;



Avoid fondaparinux or parenteral direct thrombin inhibitors;



Avoid oral dabigatran and rivaroxaban or similar agents;



Continue acute VTE treatment for at least 6 weeks postpartum for minimum of total
therapy of 3 months; and



Discontinue therapeutic LMWH at least 24 hours before labor injection or neuraxial
anesthesia

There are a number of diagnostic tests for DVT. One test is the venous ultrasonography
which is a noninvasive sensitive and accurate test to locate a thrombus in the deep and superficial
venous system. Another test is the venous doppler which is a noninvasive continuous wave
doppler used to evaluate venous flow patter. Sensitive to proximal vein thrombosis; however, it
has poor sensitivity to calf vein thrombosis. The gold standard test is a Venography which is the
use of dye injected into a vein to assess for a thrombosis (Maher, Salmond, & Pellino 2002).
Also, a lab test called a D-dimer may be used for a diagnostic test in evaluating for a DVT. A
D-dimer is a lab test showing protein derivatives of fibrin found in plasma. Plasma
concentrations are raised during a thromboembolism, infection, malignancy, pregnancy, and after
an operation. A negative test can rule out a VTE.
There are a number of tests used in the diagnosing and managing a PE. The diagnostic tests
and management tests for a PE include the following:
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Ventilation/Perfusion scan which is a less invasive test that uses x-ray and dye to assess
ventilation and pulmonary perfusion.



Pulmonary angiography which is an invasive test that uses a catheter inserted into the
pulmonary artery for the injection of dye.



Spiral test computed tomography scanning which is a noninvasive test that uses x-ray to
show pulmonary vasculature and parenchyma.



D-dimer which is a lab test showing protein derivatives of fibrin found in plasma. Plasma
concentrations are raised during a thromboembolism, infection, malignancy, pregnancy,
and after an operation.



Arterial blood gas which is a lab test used to show hypoxia.



Electrocardiogram (ECG) which may show nonspecific ST and T-wave changes. This
test is not used to make a diagnosis of PE, however; is used in the management of PE.



Echocardiogram is used to evaluate for intracardiac clot. and



Chest radiography is not conclusive for a PE, however; it may show effusion, infiltrate,
atelectasis, elevated hemidiaphragm, and be used to rule out other conditions (Maher,
Salmon, & Pellino, 2002).

There are risk identification factors for DVT and PE. The risk identification factors fall into
three categories. They are inherited, acquired, and additional risk factors. The inherited risk
factors includes


antithrombin III deficiency;



Protein C deficiency;



Protein S deficiency;
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Dysfibrinogenemia;



disorders of plasminogen and plasminogen activation;



Factor V; and



Von Willebrand disease

The acquired risk factors includes


lupus anticoagulant;



nephrotic syndrome;



paroxysmal nocturnal hemoglobinuria;



cancer;



malignancy;



stasis (cardiac heart failure, myocardial infarction, cardiomyopathy, constrictive
pericarditis, anasarca);



sepsis;



immobilization;



stroke;



polycythemia rubra vera;



inflammatory bowel disease;



obesity; and



prior thromboembolism (Maher, Salmond, & Pellino, 2002).

The additional risk factors are


surgery;
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trauma-especially to the lower extremities;



immobility;



history of DVT;



advancing age;



pregnancy or postpartum;



estrogen therapy or taking estrogen-containing oral contraceptives;



smoking; and



varicose veins (Geerts et al. 2006).

Nursing interventions need to be a part of the management of DVT and PE. The nursing
diagnosis is made and nursing interventions along with nursing outcomes are used in the care
and treatment of the patient.
Nursing Interventions are included in the following table:
Nursing Diagnosis

Nurisng Intervention Classification

Nursing Outcome

(NANDA)

(NIC)

Classification NOC)

Anxiety

Active listening, anticipatory

Anxiety self-control

guidance, anxiety reduction, calming

Concentration

techniques, coping enhancement,
emotional support, presence, relation
therapy.

Coping
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Gas exchange,

Airway management, cough

impaired

enhancement, embolus care, laboratory exchange
data interpretation, oxygen therapy,
respiratory monitoring.

Respiratory status: gas

Respiratory status:
ventilation
Tissue perfusion
Vital signs

Knowledge deficit

Risk identification, disease process,
teaching, prescribed medications,
procedures and treatments

Knowledge: medication
Knowledge: pain
management
Knowledge: prescribed
activity
Knowledge: treatment
procedures
Knowledge: treatment
regimen

Mobility: physical,

Analgesic administration, bed rest

impaired

care, body mechanics promotion,

Ambulation
Body mechanics

exercise promotion (strength training),
exercise promotion, fall prevention,

Body positioning: self-
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pain management, self-care assistance,
teaching (prescribed activity/exercise)

initiated
Client satisfaction:
functional assistance
Mobility
Transfer performance

Pain, acute

Analgesic administration, coping

Client satisfaction: pain

enhancement, environmental

management

management (comfort), pain

Discomfort level

management, positioning, simple
guided imagery, simple message,
simple relaxation techniques, teaching

Medication response
Pain control

(prescribed medication)
Pain level
Peripheral

Bed rest care, embolus precautions,

neurovascular

neurologic monitoring, pressure

dysfunction, risk for

management

Circulation status
Neurological status:
peripheral
Tissue perfusion:
peripheral

Tissue Perfusion,

Promotion of arterial circulation,

peripheral,

circulatory care (venous

Circulation status
Fluid overload severity
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ineffective

insufficiency), circulatory precautions,

Tissue integrity: skin

fluid/electrolyte management, fluid

and mucous membranes

management, hemodynamic
regulation, hypervolemia management,

Tissue perfusion:
peripheral

neurologic monitoring

Education is an important nursing consideration for patients and family in the management of
DVT and PE. Patient education on signs and symptoms of DVT & PE as well as risk of bleeding
while taking anticoagulants should be addressed.
DVT education should include the the patient will have pain tenderness over area of clot,
swelling of the thigh, tightness of the calf, and discoloration of the skin. PE education should
include that the pt may experience


dyspnea;



anxiety;



restlessness;



increased respirations;



cough, hemoptysis;



tachycardia;



syncope; and



diaphoresis.
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Patient education for prevention with lifestyle changes for DVT and PE includes


smoking cessation;



weight loss;



blood pressure control;



avoid prolong sitting or standing;



frequent exercises of lower calf muscles; and



use of compression stockings as directed.

Patient education on medication for DVT and PE should include that the patient should not
take any over-the-counter medications, supplements, or herbal remedies before telling the
provider. Protect self from injury. Take the anticoagulant at the same time every day. If a dose
is missed take as soon as possible unless it is time for next dose. If it is time for next dose do not
take a double dose just take the regular dose for the day. Have blood tests as often as directed.
Tell any healthcare provider seen for care (such as doctors, dentists, chiropractors, and home
health nurses) about taking an anticoagulant. Use a soft-bristled toothbrush. Use an electric razor
to shave. Many foods contain vitamin K, which helps blood clot. Foods high in vitamin K may
include asparagus, avocado, broccoli, and cabbage. Do not change the amount of these foods
usually ingested. Do not drink alcohol. Report any of the following: nausea; diarrhea; poor
appetite; bleeding that doesn’t stop in 10 minutes; coughing or throwing up blood; dark-colored
urine or black stools; red or black-and-blue marks on the skin; dizziness or fatigue; and chest
pain or trouble breathing.
Education of the patient and family members regarding signs and symptoms of DVT, the
prophylaxis protocol being used, and the importance of early ambulation needs to be included in
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the nursing education. The delivery of the education should be verbally and in written form. If
the patient is unable to understand the information, provide the information to the caregiver.
Discharge education should include


means of preventing a DVT;



importance of early ambulation;



benefits of prescribed prophylaxis;



signs and symptoms of DVT and PE;



generic and trade names of all medications prescribed;



early ways to recognize complications of treatment; and



any medical contact numbers.

The discharge destination for the patient is based on the level of skilled care needed by the
patient and the functional status of the patient at discharge. The optimal destination would be the
patient’s home with full return to functional status. Assistance may be needed for skilled care
and rehabilitation at a skilled facility, which should be established prior to discharge.
Trends and Controversies
Developments of the new oral anticoagulants’ positive effects include efficacy, predictability
and consistency, clinical monitoring, adherence to use and duration, and convenience. Negative
effects include issues of bleeding complications, liver enzyme elevation, influence on renal
disease, drug-to-drug interactions, no antidote to reverse bleeding, and no reliable assay to
measure effects (Nutescu et al., 2005).
Cost consideration needs to be taken into account with any new treatment modality. A cost
effectiveness analysis should be performed to include reviewing improved effectiveness, greater
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efficacy, and reduced complications. VTE continues to remain a significant concern. Use of
automated computer prompts and admission protocols may lead to using more routine
prophylaxis. It will take all health care providers, patients, and hospitals working as a team to
ensure adequate prophylactic treatment for DVT.

Project Description/Theory
The project was developed with the intent to develop a clinical guideline for nurses on the
prevention of thromboembolism in the orthopaedic patient. The final project will be presented to
the National Association of Orthopaedic Nurses for review and publication. The strength of the
project will calculated from a pre and post test on thromboembolism that will be presented to a
group of nurses at Selby General Hospital in Marietta Ohio studying for the national orthopaedic
certification test.
The Knowles (1998) learning theory will be used in teaching the thromboembolism guideline.
The theory has six principles of learning. Knowles identified six principles. The first principle is
the need to know. Adults need to know why they should learn, the reason to learn, and how it
will benefit them. The nurses participating in the orthopaedic class need to learn what will be on
the certification test and what areas they need to further study. This will help them in completing
their certification as an orthopaedic nurse. The second principle is self-concept. Adults need to
be moved into a self-directed learner where they are responsible for their own learning and the
direction it takes. The nurses will need to evaluate their own knowledge to stimulate themselves
to study on their own. The third principle is the role of experience. An adult’s experience
should be used in their new learning and the technique should include ways to include the adult’s
knowledge as a tool that they can draw upon from their experiences. The nurses will draw upon
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their past experience and education to aid them in providing evidence based-care and in studying
for the certification test. The fourth principle is readiness to learn. The nurses signed up for the
class are already expressing their readiness to learn. The fifth principle is orientation to learning.
New learning should clearly define how it will apply to life. The class will help each nurse in
providing confident and competent care to the orthopaedic patient. The sixth principle is
motivation to learn. Internal motivators are more important than the external motivators that
adults may receive for more learning. These internal motivators can come in the form of
increased job satisfaction, self-esteem, and quality of life. All of the nurses can take away a
higher sense of self-esteem expanding their current knowledge and providing a well educated
service to the nursing profession.
Knowles (1975) suggests the following: learners who take the initiative learn more and
better; enter into learning more purposefully and with greater motivation; and tend to retain
better and longer. The nurses in the orthopaedic class are volunteering their time to learn more
about their profession. They want to further their education by obtaining certification in their
field and advance their professionalism.

Capstone Project Design

The capstone project began with a pretest to be given to a class of orthopaedic nurses prior to
an education course. After the course the same test was administered again to see if there was a
change in the initial score. The course consisted of classes that span over a five week time
period. The nurses for the course came from the Mid-Ohio Valley and were employed at Selby
General Hospital in Marietta Ohio. The nurses took the class to prepare them for the National
Association of Orthopaedic exam to become certified as an orthopaedic nurse. A copy of the
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course is listed in Appendix B. There were three objectives identified for the course. The first
objective was for the participating nurses to complete the Orthopaedic Nurse Exam (ONC). The
ONC exam is based on an analysis of the practice of thousands of orthopaedic nurses across the
United States. The second objective was to encourage self study for the ONC exam. This
includes identifying a list of topics needed to cover during the individual course of study.
Encourage a collection of professional resources to use as study aids including the national
association of nurses online store. The third objective was to establish a basic foundation for the
use of evidence-based practice (EBP) in nursing. EBP is a thoughtful integration of the best
available evidence, coupled with clinical expertise that enables nurses to address healthcare
questions with an evaluative and qualitative approach. EBP allows the nurse to assess current
and past research, clinical guidelines, and other information resources in order to identify
relevant literature while differentiating between high-quality and low-quality findings. To
implement the understanding that EBP nursing consists of the following: formulating a well-built
question; identifying articles and other evidence-based resources that answer the question;
critically appraising the evidence to assess its validity; apply the evidence; and re-evaluate the
application of evidence and areas for improvement. The exact content of the classes are
explained in Appendix B. During week three the pre and post test was given for the capstone
project. A copy of the test is listed in Appendix A.

The capstone project clinical guideline was submitted to the National Association of
Orthopaedic (NAON) executive board for review. Recommendations from the executive board
were given and the paper returned for any changes. It was revised and returned to the executive
board for placement on the NAON website for suggestions from other orthopaedic certified
nurses. From this point all suggestions was considered and rewrites performed. It was then

Clinical Practice Guideline
31

submitted for publication to the Orthopaedic Nursing Journal. This submission was part of the
Evidence Based Practice and Research committee. The purpose of the committee was to
promote and facilitate orthopaedic nursing practice and research initiatives to meet the needs and
desires of NAON members and other orthopaedic health care providers. The scope of the
committee was to develop, implement, and evaluate strategies for enhancing evidence-based
orthopaedic nursing practice and research activities and tools. This clinical pathway was one of
four pathways that the committee is developing.

Project Evaluation

Evaluation of the project was the improvement of scores on the post test after the instructional
course of the class. The ultimate final evaluation was the implementation of the clinical
guideline by the National Association of Orthopaedic Nurses (NAON). The clinical guideline
went through a rigorous panel of experts for evaluation and rewrites and was approved for final
publication onto the web based site and in the journal. The panel consisted of active certified
orthopaedic registered nurses and NAON members. The members had least a baccalaureate
degree and had recent practice experience within the specialty of orthopaedic nursing and/or
familiarity with healthcare research.

Results of the Project

Twenty-three registered nurses took the class and consented to participate with the pre test
and posttest on thromboembolism. The results of all twenty-three participants are demonstrated
in the following graph displaying the pretest and the posttest.

The data was as follows:
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Participant

Pretest

Postest

1

72

90

2

80

94

3

84

98

4

60

98

5

78

100

6

90

100

7

62

98

8

60

94

9

70

98

10

72

96

11

80

98

12

84

100

13

62

96

14

78

98

15

78

98

16

60

100

17

68

98

18

74

100

19

80

98

20

84

100

21

70

94
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22

78

98

23

74

94

Group pretest

posttest

Mean

73.83

97.45

SD

8.74

2.56

SEM

1.82

0.55

23

23

N

Graph pad software (2014) was used to calculate the results. A paired t test with one tail was
used to calculate the results. The P value and statistical difference was as follows: The twotailed P value is less than 0.0001.

By conventional criteria, this difference is considered to be extremely statistically significant.
The confidence level was as follows: The mean of pretest minus posttest equals -23.64
95% confidence interval of this difference: From -27.42 to -19.85. Intermediate values used in
calculations: t=12.9753, df=21, standard error of difference=1.822

From the above results it was demonstrated that the class did increase their knowledge from
the pre and post test on the management and treatment of thromboembolism.
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Discussion

The morbidity associated with venous thromboembolism often goes unrecognized and is
preventable in many instances. Identifying patient populations at risk for venous
thromboembolism and implementing evidence-based guidelines can decrease the number of
untoward effects of this disease. Clinical pathway guidelines are valuable tools needed by nurses
in the prevention and treatment of disorders for patients. A clinical pathway guideline on
thromboembolism is a valuable tool in for the orthopaedic nurse. Education of the guideline can
increase knowledge and understanding of what prevention, interventions, and treatment are
available for the orthopaedic patient and how to apply this knowledge to everyday patient care.
Competency in identifying signs and symptoms of thromboembolism and in education of
patients and family on prevention of thromboembolism empowers the orthopaedic nurse to give
the highest quality care to the orthopaedic patient.
This clinical practice guideline provides as an educational tool based on an assessment of
current scientific and clinical research information. This tool is not intended to replace a
clinician’s independent judgment and critical thinking, but to enhance the clinician’s knowledge
base regarding the detection and prevention of venous thromboembolism in the orthopaedic
patient. The purposes of the venous thromboembolism guideline is to empower the nurse with
the best evidence-based information to assist in the identification of populations at risk for
thromboembolism and provide the best care available in the treatment and prevention of
thromboembolism.
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Appendix A

Pre-Test Examination for Thromboembolism
Translating Evidence Based Research on Venous
Thromboembolism into Practice
Purpose/Goal
To educate orthopaedic nurses about evidence-based practice to improve outcomes for
orthopaedic surgical patients at risk for thromboembolism.

Objectives
After instructional course on evidence-based practice and VTE the orthopaedic nurse will be able
to:
1. Explain how evidence-based practice can improve patient outcomes with VTE
2. Define VTE
3. Describe the vascular pathophysiology that results in deep vein thrombosis and
pulmonary embolism
4. Discuss the effects of VTE
5. Describe why surgical patients are at an increased risk for developing VTE
6. Compare prevention and treatment options for VTE

Questions
1. The components of Virchow’s traid include venous stasis, vessel wall damage, and
a. vessel length
b. coagulation treatment
c. coagulation changes
d. vessel repair

2. Which of the following is a symptom or symptoms of a deep vein thrombosis?
a. warmth to the area
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b. localized tenderness or pain
c. localized skin redness
d. all of the above
3. Venous thromboembolism consists of which of the following?
a. deep vein thrombosis
b. pulmonary embolism
c. a only
d. a & b
4. Which of the following is the most deadly complication of a deep vein thrombosis?
a. atherosclerosis
b. pulmonary embolism
c. vascular rupture
d. infection
5. Factors that predispose orthopaedic surgical patients to the development of a VTE
include:
a. dehydration
b. immobility
c. b only
d. a & b
6. Nurses should encourage patients to:
a. mobilize early
b. perform breathing exercises
c. a only
d. a & b
7. The primary complication of intermittent pneumatic devices is

Clinical Practice Guideline
45

a. noncompliance
b. delayed ambulation
c. a only
d. a & b
8. Symptom or symptoms of a pulmonary embolism are which of the following?
a. unexplained shortness of breath
b. tachycardia
c. nervousness
d. all of the above
9. Adverse reaction or reactions to heparin include which of the following?
a. hematoma
b. compartment syndrome
c. thrombocytopenia
d. all of the above
10. The prevalence of VTE is increasing due to which of the following?
a. aging of the population
b. more complicated surgeries
c. longer survival of patients with predisposing conditions
d. all of the above
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Appendix B

Orthopaedic Course Selby Hospital
Angela Miller MSN, ONP-C, FNP-BC
Purpose/Goal
To provide an instructional course to orthopaedic nurses interested in completing the national
orthopaedic certification exam. This course will help to improve orthopaedic nursing knowledge
while encouraging the practice of critical thinking skills in the implementation of evidence-based
practice.
Objectives
1. To complete the Orthopaedic Nurse Exam upon finishing this course. The ONC exam is
based on an analysis of the practice of thousands of orthopaedic nurses across the United
States. From that analysis, a test blueprint is constructed to determine what percentage of
questions will cover each area of practice (content areas) and each nursing role (test
objectives).The ONC examination contains 150 questions. Of these, 135 are scored; the
remaining 15 questions are pilot items, and the candidate’s performance on those questions
will not be reflected in the exam score. A raw score of 97 is needed to pass the examination,
equaling 72%
2. To encourage self study for the ONC exam. This includes identifying a list of topics needed
to cover during the individual course of study. Encourage a collection of professional
resources to use as study aids including the national association of nurses on line store.
3. To establish a basic foundation for the use of evidence-based practice (EBP) in nursing.
EBP is a thoughtful integration of the best available evidence, coupled with clinical
expertise that enables nurses to address healthcare questions with an evaluative and
qualitative approach. EBP allows the nurse to assess current and past research, clinical
guidelines, and other information resources in order to identify relevant literature while
differentiating between high-quality and low-quality findings. To implement the
understanding that EBP nursing consists of the following: formulating a well-built
question; identifying articles and other evidence-based resources that answer the question;
critically appraising the evidence to assess its validity; apply the evidence; and re-evaluate
the application of evidence and areas for improvement.

Course Instruction
Week 1: Degenerative Joint Disease



Osteoarthritis
Charcot joints

2 hours
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Chondromalacia of the patella
Posttraumatic arthritis
Hallux valgus

Week 2: Test on Degenerative Joint Disease

30 minutes

Inflammatory Disease

30 minutes









Rheumatoid arthritis
Systemic lupus erythematosus
Psoriatic arthritis
Systemic sclerosis
Ankylosing spondylitis
Bursitis
fibromyalgia

Metabolic Bone Disease





Osteoporosis
Paget’s disease
Gout
Avascular necrosis

Neuromuscular /Pediatric/Congenital






30 minutes

30 minutes

Osteogenesis imperfect
Slipped capital femoral epiphysis
Osgood-Schlatter disease
Tibial torsion
Spina bifida

Week 3: Test on Inflammatory Disease, Metabolic Bone Disease, and Neuromuscular/
Pediatric/Congenital
30 minutes
Oncology: Musculoskeletal Tumors




Osteosarcoma
Ewing’s sarcoma
Giant cell tumor of the bone

Orthopaedics in the operating room


30 minutes

Total hip arthroplasty

30 minutes
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Total knee arthroplasty
Total shoulder arthroplasty
Thromboembolism- (pretest and posttest)

Sports Injuries









1 hour

Shoulder injuries
Elbow injuries
Wrist injuries
Hand injuries
Hip injuries
Knee injuries
Ankle injuries
Foot injuries

Week 4: Test Oncology/Orthopedic/Sports Injuries

30 minutes

Orthopaedic Trauma

1.5 hours







Types of fractures
Dislocations
Emergency treatment
Complications
Nursing management

Week 5: Test Orthopedic Trauma

30 minutes

Question & Answers/Preparing for the Exam

30 minutes

Review

1 hour

